Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications.

Shi, Haotian; Wei, Wei; Peng, Rong; Chen, Haimin; Zhou, Nian; Wu, Lixia; Yu, Wenjun; Zhao, Wenhao; Hou, Jian; Zhou, Fan

Shi, Haotian; Wei, Wei; Peng, Rong; Chen, Haimin; Zhou, Nian; Wu, Lixia; Yu, Wenjun; Zhao, Wenhao; Hou, Jian; Zhou, Fan.

Affiliation

Shi H; Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.
Wei W; Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.
Peng R; Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.
Chen H; Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.
Zhou N; Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.
Wu L; Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.
Yu W; Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.
Zhao W; Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.
Hou J; Department of Hematology, Renji Hospital Affiliated to the School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Zhou F; Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.

Front Oncol ; 13: 1185991, 2023.

Article in En | MEDLINE | ID: mdl-37284198

Key words

RRMM; cyclophosphamide; prednisone; response to therapy; safety; survival

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Oncol Year: 2023 Document type: Article Affiliation country: China Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google